Neuromyelitis optica spectrum disorder (NMOSD)

NMOSD

NMOSD is a chronic, complement-mediated autoimmune disease of the CNS, characterised by frequent and unpredictable attacks that lead to irreversible damage1–4 

Diagnosing NMOSD

Discover the key steps in the diagnosis of NMOSD

Burden of disease

Learn more about the burden of NMOSD on patients

Symptoms of NMOSD

Recognise the common signs and symptoms of NMOSD

Treatment types

Understand the need for an individualised treatment approach
ULTOMIRIS® is indicated in the treatment of adult patients with NMOSD who are anti-aquaporin 4 (AQP4) antibody-positive.5
Please consult the Summary of Product Characteristics prior to prescribing.

About ULTOMIRIS®

Learn more

ULTOMIRIS® in the treatment of AQP4 antibody-positive NMOSD

MECHANISM of Action

Learn more

Review and explore the mechanism of action of ULTOMIRIS®

Efficacy and safety

Learn more

Explore clinical data looking at the efficacy & safety of ULTOMIRIS®

Dosing calculator

Learn more

Access our easy-to-use tool to calculate your patient's dosing requirements

Patient stories

Listen to Lelainia Lloyd share her experience as a person living with NMOSD

Dosing and administration

Learn about the weight-based dosing regimen of ULTOMIRIS®

patient profiles

Which of your patients with AQP4 Ab+ NMOSD can you help strive for zero relapses?
Sign up now to be informed of our upcoming symposia, our latest educational updates, and to be alerted to our webinars, hosted by world leading experts in NMOSD.
Keep me up to date

FIRST NAME*

SURNAME*

DISEASE AREA OF INTEREST*

Specialty*

EMAIL*

COUNTRY*
SOLIRIS® is indicated in the treatment of adult patients with NMOSD who are anti-aquaporin 4 (AQP4) antibody-positive with a relapsing course of the disease.6
Please consult the Summary of Product Characteristics prior to prescribing.
advance I am a healthcare professional registered in the EU I am not a
healthcare professional

About Soliris®

Learn more

SOLIRIS® in the treatment of AQP4 antibody-positive NMOSD

MECHANISM of action

Learn more

Review and explore the mechanism of action of SOLIRIS®

EFFICACY & SAFETY

Learn more

Explore clinical data looking at the efficacy & safety of SOLIRIS®

Adverse Event Reporting

Please report any adverse reactions via your national reporting system. Adverse events should also be reported to Alexion pharmaceuticals by the following link: https://contactazmedical.astrazeneca.com
AChR, anti-acetylcholine receptor; gMG, generalised myasthenia gravis.
Wingerchuk DM, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177–189. Weinshenker BG, et al. Neuromyelitis Spectrum Disorders. Mayo Clin Proc. 2017;92(4):663–679. Jarius S, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation. 2012;9(1):14. Chamberlain JL, et al. Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review. J Neurol. 2021;268(5):1643–1664. ULTOMIRIS® Summary of Product Characteristics available at https://www.ema.europa.eu/en/documents/product-information/ultomiris-epar-product-information_en.pdf. Last accessed: May 2024. SOLIRIS® Summary of Product Characteristics available at https://www.ema.europa.eu/en/documents/product-information/soliris-epar-product-information_en.pdf. Last accessed: May 2024.